Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004
GROTON, Conn.–(BUSINESS WIRE)–Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced that the Company’s first-in-human Phase 1 clinical study initiated today with the dosing of a first subject with AST-004. The promising investigational therapeutic, AST-004, is being advanced as a potential acute treatment for stroke … [Read more…]
